Profilo
Alan Tyndall is the founder of Magenta Therapeutics, Inc. (2015).
He is currently a Professor-Emeritus at the University of Basel (since 1991) and serves as Secretary at the World Scleroderma Foundation.
Mr. Tyndall received his undergraduate degree from the University of Sydney in 1972.
Mr. Tyndall is also the founder of Iterata AG.
Posizioni attive di Alan Tyndall
| Società | Posizione | Inizio |
|---|---|---|
| University of Basel | Corporate Officer/Principal | 01/01/1991 |
| World Scleroderma Foundation | Corporate Secretary | - |
| Iterata AG | Founder | - |
Precedenti posizioni note di Alan Tyndall
| Società | Posizione | Fine |
|---|---|---|
| MAGENTA THERAPEUTICS | Founder | - |
Formazione di Alan Tyndall
| The University of Sydney | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
| World Scleroderma Foundation | |
| Iterata AG |
- Borsa valori
- Insiders
- Alan Tyndall
